Pharma BD Deal Intelligence
Roche's unconventional "alliance-not-merger" structure with Chugai turned a ~$1.3-1.6B controlling-stake deal into a multi-decade engine of blockbuster drugs (Actemra, Alecensa, Hemlibra) and a stake now worth tens of billions.
Full analysis, sources & comparables →Roche and Chugai entered alliance with the Swiss firm becoming majority shareholder; deal cited as a template for Western pharma to enter the Japanese market…
With the addition of Roche's anticancer drugs to its product lineup, Chugai achieved top-tier market share in Japan's oncology field; the alliance dramatically…
Roche acquired 50.1% of Chugai for YEN 155-198B; Chugai merged with Nippon Roche while remaining listed on the Tokyo Stock Exchange and maintaining management…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Strategic alliance giving Roche 50.1% majority stake in Chugai; full alliance start October 2002. Nippon Roche merged into Chugai.
Roche's unconventional "alliance-not-merger" structure with Chugai turned a ~$1.3-1.6B controlling-stake deal into a multi-decade engine of blockbuster drugs (Actemra, Alecensa, Hemlibra) and a stake now worth tens of billions.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. (this deal) | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
| Roche Holding AG / GlycArt Biotechnology AG | 2005 | $182M | 80 |
← Browse all deals · How we score deals
More: 2002 deals · Roche Holding AG deals